This installation features the key University of North Carolina (UNC) partnerships that have been established between university, industry, and nonprofit as they work together to cure specific disease states.
The groundbreaking partnership between UNC Chapel Hill and GlaxoSmithKline to find a cure for AIDS. A first-of-its-kind public-private partnership, the two organizations have combined resources to launch the HIV Cure center and Qura Therapeutics.
UNC is also conducting phase III-clinical trials of a malaria vaccine in Malawi in partnership with the PATH Malaria Vaccine Initiative and GlaxoSmithKline. The phase III trials of the world’s most clinically advanced malaria vaccine candidate, known as RTS,S, got underway recently h in Lilongwe, Malawi. The first dose of this investigational vaccine was administered at UNC Project-Malawi under the auspices of the Institute for Global Health and Infectious Diseases at UNC. This follows the initiation of the phase III trial in Tanzania in May 2009. GlaxoSmithKline Biologicals developed and manufactures the vaccine, and the PATH Malaria Vaccine Initiative (MVI) is providing technical and financial support for the trial, which is expected to enroll up to 16,000 children and infants in six other countries throughout Africa.